Brief: LAVA Therapeutics Announces Treatment Of First Patient In Phase 1/2A Clinical Trial Of Lava-051 For Multiple Hematological Malignancies
13/07/2021 12:36
July 13 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA THERAPEUTICS ANNOUNCES TREATMENT OF FIRST PATIENT IN
PHASE
1/2A CLINICAL TRIAL OF LAVA-051 FOR MULTIPLE HEMATOLOGICAL
MALIGNANCIES
Source text for Eikon: ID:nGNXbL4MNF
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM